MA32467B1 - Derives de piperidinyle agonistes de gpcr - Google Patents

Derives de piperidinyle agonistes de gpcr

Info

Publication number
MA32467B1
MA32467B1 MA33508A MA33508A MA32467B1 MA 32467 B1 MA32467 B1 MA 32467B1 MA 33508 A MA33508 A MA 33508A MA 33508 A MA33508 A MA 33508A MA 32467 B1 MA32467 B1 MA 32467B1
Authority
MA
Morocco
Prior art keywords
gpcr agonists
piperidinyl derivatives
gpcr
piperidinyl
derivatives
Prior art date
Application number
MA33508A
Other languages
Arabic (ar)
English (en)
Inventor
Lisa Sarah Bertram
Matthew Colin Thor Fyfe
Revathy Perpetua Jeevaratnam
John Keily
Thomas Martin Krulle
Chrystelle Marie Rasamison
Colin Peter Sambrook-Smith
Simon Andrew Swain
Original Assignee
Prosidion Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0812622A external-priority patent/GB0812622D0/en
Priority claimed from GB0812646A external-priority patent/GB0812646D0/en
Priority claimed from GB0902391A external-priority patent/GB0902391D0/en
Application filed by Prosidion Ltd filed Critical Prosidion Ltd
Publication of MA32467B1 publication Critical patent/MA32467B1/fr

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Diabetes (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

L'invention concerne des composés représentés par la formule (i) ou des sels de ceux-ci pharmaceutiquement acceptables, qui sont des agonistes des gpcr et qui conviennent pour le traitement du diabète et de l'obésité.
MA33508A 2008-07-10 2011-01-10 Derives de piperidinyle agonistes de gpcr MA32467B1 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB0812622A GB0812622D0 (en) 2008-07-10 2008-07-10 Compounds
GB0812646A GB0812646D0 (en) 2008-07-10 2008-07-10 Compounds
GB0902391A GB0902391D0 (en) 2009-02-13 2009-02-13 Compounds
PCT/GB2009/050825 WO2010004343A1 (fr) 2008-07-10 2009-07-10 Agonistes des récepteurs couplés aux protéines g (gpcr) piperidinyles

Publications (1)

Publication Number Publication Date
MA32467B1 true MA32467B1 (fr) 2011-07-03

Family

ID=41070447

Family Applications (1)

Application Number Title Priority Date Filing Date
MA33508A MA32467B1 (fr) 2008-07-10 2011-01-10 Derives de piperidinyle agonistes de gpcr

Country Status (15)

Country Link
US (1) US20110269734A1 (fr)
EP (1) EP2321297A1 (fr)
JP (1) JP2011527331A (fr)
KR (1) KR20110036609A (fr)
CN (1) CN102083813A (fr)
AU (1) AU2009269772A1 (fr)
CA (1) CA2728042A1 (fr)
CL (1) CL2011000051A1 (fr)
EA (1) EA201170151A1 (fr)
IL (1) IL209978A0 (fr)
MA (1) MA32467B1 (fr)
MX (1) MX2011000060A (fr)
PE (1) PE20110329A1 (fr)
WO (1) WO2010004343A1 (fr)
ZA (1) ZA201008955B (fr)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009127949A1 (fr) * 2008-04-17 2009-10-22 Pfizer Inc. Composés aryl carboxamides de 4-[3-(aryloxy)benzylidène]-3-méthyl pipéridine utiles comme inhibiteurs de la faah
GB0904284D0 (en) 2009-03-12 2009-04-22 Prosidion Ltd Compounds for the treatment of metabolic disorders
GB0904287D0 (en) 2009-03-12 2009-04-22 Prosidion Ltd Compounds for the treatment of metabolic disorders
GB0904285D0 (en) 2009-03-12 2009-04-22 Prosidion Ltd Compounds for the treatment of metabolic disorders
KR20180028070A (ko) 2009-05-13 2018-03-15 길리애드 파마셋 엘엘씨 항바이러스 화합물
US8618076B2 (en) 2009-05-20 2013-12-31 Gilead Pharmasset Llc Nucleoside phosphoramidates
TWI598358B (zh) 2009-05-20 2017-09-11 基利法瑪席特有限責任公司 核苷磷醯胺
TW201113269A (en) 2009-06-24 2011-04-16 Boehringer Ingelheim Int New compounds, pharmaceutical composition and methods relating thereto
NZ596445A (en) 2009-06-24 2013-04-26 Boehringer Ingelheim Int New compounds, pharmaceutical composition and methods relating thereto
WO2011113947A1 (fr) 2010-03-18 2011-09-22 Boehringer Ingelheim International Gmbh Combinaisons d'agonistes de gpr119 et d'inhibiteurs de dpp-iv, linagliptine, pour le traitement du diabète et d'états apparentés
GB201006167D0 (en) 2010-04-14 2010-05-26 Prosidion Ltd Compounds for the treatment of metabolic disorders
GB201006166D0 (en) 2010-04-14 2010-05-26 Prosidion Ltd Compounds for the treatment of metabolic disorders
TW201209054A (en) 2010-05-28 2012-03-01 Prosidion Ltd Novel compounds
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
AR083904A1 (es) 2010-11-18 2013-04-10 Prosidion Ltd Derivados de 1,4-pirrolidinas disustituidos y 3-il-aminas y sus usos en el tratamiento de desordenes metabolicos
GB201114389D0 (en) 2011-08-22 2011-10-05 Prosidion Ltd Novel compounds
WO2012138845A1 (fr) 2011-04-08 2012-10-11 Merck Sharp & Dohme Corp. Composés à cyclopropyle substitué, compositions contenant de tels composés et méthodes de traitement
EP2720544B1 (fr) 2011-06-16 2016-12-21 Merck Sharp & Dohme Corp. Composés cyclopropylés substitués, compositions contenant de tels composés et procédés de traitement
WO2013037390A1 (fr) 2011-09-12 2013-03-21 Sanofi Dérivés amides d'acide 6-(4-hydroxyphényl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylique en tant qu'inhibiteurs de kinase
AU2012308295B2 (en) 2011-09-16 2017-10-26 Gilead Sciences, Inc. Methods for treating HCV
WO2013045413A1 (fr) 2011-09-27 2013-04-04 Sanofi Dérivés d'amide d'acide 6-(4-hydroxyphényl)-3-alkyl-1h-pyrazolo[3,4-b] pyridine-4-carboxylique utilisés comme inhibiteurs de kinase
EP2760855B1 (fr) 2011-09-30 2017-03-15 Merck Sharp & Dohme Corp. Composés de cyclopropyle substitués, compositions contenant ces composés ainsi que leur utilisation pour le traitement du diabète de type 2
WO2013062838A1 (fr) 2011-10-24 2013-05-02 Merck Sharp & Dohme Corp. Composés de pipéridinyle substitués utilisés comme agonistes du récepteur gpr119
AU2012339870B2 (en) 2011-11-15 2017-06-29 Merck Sharp & Dohme Corp. Substituted cyclopropyl compounds useful as GPR119 agonists
MY172166A (en) 2013-01-31 2019-11-15 Gilead Pharmasset Llc Combination formulation of two antiviral compounds
EP3650014B1 (fr) 2013-08-27 2021-10-06 Gilead Pharmasset LLC Formulation de combinaison de deux composés antiviraux
WO2018068295A1 (fr) * 2016-10-14 2018-04-19 Merck Sharp & Dohme Corp. Dérivés d'ether d'aryl et d'heteroaryle en tant qu'agonistes des récepteurs β x du foie, compositions et utilisation associée
JP2022552655A (ja) * 2019-10-07 2022-12-19 キャリーオペ,インク. Gpr119アゴニスト
PH12022552277A1 (en) 2020-02-28 2024-03-04 Kallyope Inc Gpr40 agonists
CN117321059A (zh) 2021-05-21 2023-12-29 吉利德科学公司 用于治疗寨卡病毒感染的四环化合物
US12037340B2 (en) 2021-05-21 2024-07-16 Gilead Sciences, Inc. Pentacyclic derivatives as Zika virus inhibitors

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2308840A1 (fr) * 2005-06-30 2011-04-13 Prosidion Limited Agonistes de GPCR

Also Published As

Publication number Publication date
EA201170151A1 (ru) 2011-08-30
IL209978A0 (en) 2011-02-28
PE20110329A1 (es) 2011-06-03
EP2321297A1 (fr) 2011-05-18
ZA201008955B (en) 2011-08-31
CN102083813A (zh) 2011-06-01
MX2011000060A (es) 2011-02-22
US20110269734A1 (en) 2011-11-03
AU2009269772A1 (en) 2010-01-14
JP2011527331A (ja) 2011-10-27
CA2728042A1 (fr) 2010-01-14
KR20110036609A (ko) 2011-04-07
CL2011000051A1 (es) 2012-03-16
WO2010004343A1 (fr) 2010-01-14

Similar Documents

Publication Publication Date Title
MA32467B1 (fr) Derives de piperidinyle agonistes de gpcr
ATE557024T1 (de) Piperidinverbindungen als gpcr-agonisten
ATE557023T1 (de) Piperidinylverbindungen als gpcr-agonisten
MX2009007180A (es) Agonistas del receptor acoplado a la proteina g de la piperidina.
EA200900877A1 (ru) Пиперидиновые агонисты gpcr
NO20084307L (no) Heterocykliske GPCR agonister
DOP2012000006A (es) Agonista de gpr119
EA201170227A1 (ru) Имидазолкарбоксамиды
EA201170872A1 (ru) Ингибиторы протеинкиназы
CY1112474T1 (el) Πιπεριδινικοι gpcr αγωνιστες
EA201390609A1 (ru) ПРОИЗВОДНЫЕ ГИДАНТОИНА, ПОЛЕЗНЫЕ В КАЧЕСТВЕ ИНГИБИТОРОВ Kv3-КАНАЛОВ
EA201100503A1 (ru) Глюкозидные производные и их применения
MA32508B1 (fr) Composes organiques
MY153915A (en) Organic compounds
NO20083726L (no) Spiroindolinon derivater
MX354402B (es) Inhibidores de molecula pequeña del dominio de homologia de pleckstrin y metodos para usar los mismos.
EA201200323A1 (ru) Соединения и композиции, как ингибиторы протеинкиназы
NO20085099L (no) Puritonderivativer som HM74A agonister
EA200801428A1 (ru) Производные пиридиазинона для лечения опухолей
MY147649A (en) Benzimidazole derivatives useful in treatment of vallinoid receptor trpv1 related disorders
UA107784C2 (en) Inhibitor of melanin production
MX2012004264A (es) Derivados de sulfoxidos para el tratamiento de tumores.
MA32723B1 (fr) Derives d'anilino-pyrimidine a substitution sulfoximine en tant qu'inhibiteurs de cdk, leur preparation et leur utilisation comme medicaments
CO6382123A2 (es) Antagonistas de la via hedgehog de ftalazina disustituida
EA201001747A1 (ru) Бензоксазиноновые производные, действующие в качестве агониста бета-2-адренорецептора, для лечения респираторных расстройств